Eli Lilly gave investors a big reason to cheer on Thursday, lifting its full-year revenue forecast by $5 billion after a new Medicare pilot program brought in more than half a million new customers aged 65 and older. The news sent shares up more than 6% in a single day, underscoring how central the weight-loss drug boom has become to the company's fortunes.
The Indianapolis-based drugmaker now expects 2026 revenue of $91 billion to $92 billion, according to Reuters, up from its previous guidance. The upgrade comes on the back of stronger-than-expected third-quarter results, with revenue hitting $24.4 billion and adjusted earnings per share of $7.48—both beating Wall Street's forecasts.
What's driving the growth?
The main engines remain Lilly's injectable diabetes and weight-loss drugs, Mounjaro and Zepbound. These GLP-1 medications, which help control blood sugar and suppress appetite, have become blockbusters. International sales of Mounjaro jumped 93% year over year, a sign that demand is spreading well beyond the U.S. market.
The Medicare pilot is a notable new piece of the puzzle. By signing up more than 500,000 people aged 65 and up, Lilly is tapping into a demographic that has historically been underserved by these drugs, partly because of cost and partly because Medicare coverage for weight-loss drugs has been limited. The pilot appears to be opening a new channel for growth, and the company is clearly betting that this population will drive meaningful sales.
However, not everything went perfectly. Lilly's oral weight-loss pill, Foundayo, missed sales estimates in the quarter. While the injectable drugs have been the stars, the oral pill was seen as a potential game-changer because it offers a more convenient option for patients who prefer not to take injections. The miss is a reminder that even in a booming category, not every product hits the mark right away.
Why this matters for investors
For everyday investors, the key takeaway is that Lilly's growth story is far from over. The company has repeatedly raised its outlook as demand for its GLP-1 drugs continues to surge. This latest raise of $5 billion is a significant jump, and it signals that management sees strong momentum continuing into next year.
But there are also cautionary notes. The Foundayo miss shows that competition and execution risks remain. Rivals like Novo Nordisk are also pushing hard in the weight-loss space, and pricing pressures could emerge as more options hit the market. Additionally, the Medicare pilot's success could attract regulatory scrutiny or lead to broader coverage changes that might affect pricing.
For those holding Lilly stock, the news is clearly positive. The company is not just beating expectations; it's raising the bar for the future. For those watching from the sidelines, the question is whether the stock's valuation already reflects this optimism. Lilly trades at a premium to many peers, and any stumble in the GLP-1 franchise could hit the shares hard.
What to watch next
Investors will be watching several things in the coming months. First, how quickly the Medicare pilot expands and whether it becomes a permanent program. Second, whether Foundayo can regain momentum and compete effectively with the injectables. Third, how international sales continue to grow, especially in markets like Europe and Asia where GLP-1 adoption is still in early stages.
Lilly's results also have broader implications for the healthcare sector. The success of these drugs is reshaping how obesity and diabetes are treated, and that has ripple effects for insurers, employers, and other drugmakers. As Lilly and Merck both beat Q3 forecasts on blockbuster drug sales, it's clear that the pharma sector is enjoying a strong moment.
For those looking at the bigger picture, the GLP-1 boom is also drawing attention to other companies in the space. Serval's recent $150 million raise shows that investors are willing to back new entrants in adjacent markets, though the weight-loss drug arena remains dominated by a few big players.
Ultimately, Lilly's latest update is a reminder that in the world of investing, momentum matters. The company has delivered again, and it's raising its sights. But as with any high-flying stock, it pays to keep an eye on the risks as well as the rewards.
